Xeris Pharmaceuticals Inc (XERS NASDAQ) stock market data APIs
$7.0286
-0.02(-0.3%)
as of February 6, 2026
Try our APIs with
free plan!
Xeris Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Prev. Close
7.0286
Open
7.0068
High
7.045
Low
6.9615
52 wk Range
3.45-10.08
Market Cap
1 163 M
Shares Outstanding
166 M
Revenue
266 M
EPS
0.0035
Beta
0.934
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Xeris Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Xeris Pharmaceuticals Inc data using free add-ons & libraries
Get Xeris Pharmaceuticals Inc Fundamental Data
Xeris Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 266 M
- EBITDA: 28 036 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: 0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Xeris Pharmaceuticals Inc News
New
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away
Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for relacorilant, its investigational treatment for Cushing’s syndrome. The agen...
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
Key Points It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock.10 stocks we like better than Xeris Biopharma › A competitor's setback ...
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
Key Points It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock. 10 stocks we like better than Xeris Biopharma › A competitor's setback...
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research. In this article, we will summ...
Get Xeris Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
